United Therapeutics

United Therapeutics Corporation is a biotechnology company dedicated to developing and commercializing innovative therapies that address serious and life-threatening diseases. Headquartered in Silver Spring, Maryland, the company specializes in treatments for pulmonary arterial hypertension (PAH) and other rare conditions, providing life-extending solutions to patients with limited options.

United Therapeutics has built a robust portfolio of FDA-approved medicines, including Remodulin®, Tyvaso®, Orenitram®, Adcirca®, and Unituxin®, which are primarily used to treat PAH and pediatric neuroblastoma. These therapies are designed to improve both the quality and duration of life for individuals facing chronic and complex medical challenges. The company continues to invest in next-generation delivery systems like dry powder inhalers and implantable pumps to enhance patient convenience and treatment adherence.

Beyond its pharmaceutical offerings, United Therapeutics is a leader in organ manufacturing and regenerative medicine. Through its subsidiaries—Lung Biotechnology PBC and Revivicor—the company is pioneering technologies in xenotransplantation, including the development of bioengineered organs, with the long-term goal of eliminating the organ transplant shortage. This includes engineering donor pigs to provide lungs, kidneys, and hearts compatible with human recipients.

United Therapeutics operates with a strong commitment to sustainability, equity, and public benefit. In 2021, it became one of the first publicly traded public benefit corporations (PBCs), formalizing its mission to balance profit with purpose. The company also leads in green building design, having developed net-zero energy facilities and earned recognition for its environmental initiatives.

With its integrated approach to drug development, organ engineering, and patient advocacy, United Therapeutics is reshaping the future of healthcare—one breakthrough at a time.